Dr. Harry L. Leider, Renowned Healthcare Expert, Joins Ameritox As Chief Medical Officer
Ameritox, the U.S. leader in pain prescription monitoring, is pleased to announce that Dr. Harry L. Leider, MD, MBA, FACPE, has joined the company as chief medical officer and senior vice president. Dr. Leider will lead a variety of progressive initiatives, ranging from clinical research, to physician education, as well as strategic programs related to product development and payor partnerships.
For more than 20 years, Dr. Leider has been an effective and widely-respected force for change in the healthcare industry, helping to develop and establish the disease management specialty for Medicare recipients and other populations with special medical needs. He has held senior leadership roles with a diverse range of healthcare companies, including XLHealth, Care Improvement Plus, IFI Health Solutions, and Harvard Community Health Plan.
Dr. Leider also has held numerous national healthcare leadership roles. He is currently an officer on the Board of the American College of Physician Executives serving as the organization’s president-elect. He was a founding board member of the Disease Management Association of America (DMAA) and currently chairs its Medicare Committee. He serves on the Board of the Institute of Aging at the University of Pennsylvania. A frequent speaker at universities, medical schools, and national conferences, Dr. Leider has authored numerous peer-reviewed articles as well as chapters in multiple books, including The Essentials of Medical Management and Practicing Medicine in the 21st Century.
“Dr. Leider has inspired and educated other physicians in leadership positions on how to best manage and achieve success for their own practices and organizations. With his experience and insight, he is uniquely qualified to move Ameritox forward in achieving its next level of growth and sophistication,” said Ancelmo E. Lopes, Ameritox CEO. “I am personally very excited and pleased to have him with us.”
Dr. Leider obtained a BA from Pennsylvania State University and earned his MD from the University of Pennsylvania School of Medicine. While he was a Robert Wood Johnson Clinical Scholar, he earned his MBA from the University of Washington. In addition to being board-certified in Internal Medicine, he is board-certified in Medical Management and is a fellow of the American College of Physician Executives. He served for six years as an attending physician at Brigham and Women’s Hospital in Boston and as a faculty member at Harvard Medical School. Dr. Leider is currently a Senior Scholar in the Department of Health Policy and Outcomes at Thomas Jefferson University.
Ameritox is the nation’s leader in pain prescription monitoring. Only Ameritox offers RxGuardian(SM), the most thorough and personalized lab report available, and the only report that can help physicians assess whether a patient is taking their pain medication consistent with the prescribed dosage plan. By comparing normalized values to expected prescription-specific ranges, RxGuardian assists pain practitioners in protecting their patients by providing information to help assess compliance based on prescription regimens. RxGuardian also provides peace of mind to physicians and protection to their practice by providing data to help ensure that patients are taking pain medications as prescribed. With its headquarters in Baltimore, MD and with laboratory facilities in Midland, TX, Ameritox processes thousands of specimens everyday. For additional information about the Company, please visit our website at www.ameritox.com.